In addition, Brd4 has also been considered a promising therapeutic target in acute myeloid leukemia (AML) because of its ability to sustain P-TEFb-dependent c-Myc expression (Blobel et al., 2011; Zuber et al., 2011). The gene discussed is MYC; the disease is acute myeloid leukemia.